如果美国静脉曲张治疗设备市场ze was valued at USD 461.5 million in 2018 and is expected to expand at a CAGR of 5.5% over the forecast period. The rise in investments by the manufacturers to introduce innovative products in the market is likely to boost the growth. An increase in the prevalence of varicose veins coupled with the growing geriatric population is anticipated to further fuel the growth in the U.S.
Minimally invasive varicose vein surgeries result in reduced patient discomfort, postoperative pain, and bruising. Unlike surgical stripping, patients who have undergone occlusion procedures can immediately resume their daily routine activities. Minimally invasive procedures are increasingly being performed at physician offices and ambulatory centers, instead of hospital settings. This increases patient comfort and convenience and reduces patient anxiety of undergoing surgery in hospital settings.
Varicose vein treatment surgeries are evolving to become noninvasive or minimally invasive in nature. Reduced risk of infections and scarring associated with invasive surgeries is anticipated to drive the preference for non-invasive surgeries. Noninvasive methods reduce the duration of hospital stay, thereby saving time as well as cost. As a result, there is a rise in preference for treatment options, such as foam sclerotherapy, endovenous laser, and radiofrequency ablation over conventional surgeries.
Venous ablation techniques can be performed without a groin incision, eliminating the risk of wound infection, especially in obese patients. These techniques are less time consuming and efficient for short- as well as long-term treatment of varicose veins. Post-operative pain is very limited with higher wavelengths and with radial fiber in case of ablation procedures.
Aging may considerably affect the structure and functions of the veins. One out of every two people above 50 years is affected by varicose veins. An investigational study indicated that about 42% of men and 58% of women belonging to the age group of 66 to 96 years suffer from varicose veins.
Based on type, the U.S. varicose vein treatment devices market is categorized into endovenous ablation, sclerotherapy, and surgical ligation and stripping. The endovenous ablation segment is further categorized into laser ablation and radiofrequency ablation. Sclerotherapy segment accounted for the largest market share in 2018, due to easier accessibility, efficiency to treat varicose veins, and favorable reimbursement scenario. Sclerotherapy procedure eliminates the need for prolonged hospital stay and patients often leave with minimal bruising and scarring.
Various organizations undertake initiatives for raising awareness and the treatment rate of vein diseases. Numerous market players are investing in the development of innovative and effective products. Commercialization of various products in the recent years is anticipated to further boost the growth. VenaSeal closure system by Medtronic is the latest addition to the varicose vein treatment options. According to the clinical performance data for VenaSeal, it is anticipated to be the most effective treatment options in the forthcoming years.
Rising demand for the treatment of vein diseases is owing to the significant presence of aesthetically conscious population base in the country. Patients are willing to undergo cosmetic surgeries due to safety and evident results. The demonstration of safety and efficacy of laser treatments has reduced the apprehension regarding cosmetic procedures. This factor is projected to further fuel the demand for the treatment devices in the forthcoming years.
Some of the key players operating in the market are Medtronic plc; AngioDynamics, Inc.; Syneron Medical Ltd.; Lumenis Ltd.; Biolitec AG; Eufoton srl; Energist Group; Quanta Systems S.p.A.; and Teleflex, Inc. The companies engage in regional expansion, new product development, and product portfolio expansion to strengthen their market presence. Some of the market players opt to purchase the products directly from the manufacturers and sell them as distributors.
In terms of regional footprint, Medtronic and Teleflex, Inc. were some of the leading companies in 2018. Medtronic is present in more than 160 countries, whereas, Teleflex, Inc. operates in about 150 countries. Teleflex, Inc. expanded through various mergers and acquisitions in recent years. For instance, in February 2017, the company acquired Vascular Solutions, Inc. The acquisition propelled the Teleflex vascular and interventional access product portfolios. Furthermore, recently, in April 2017, Teleflex acquired Pyng Medical through a merger, after which the company runs as a subsidiary of Teleflex Canada. Through this acquisition, the company expanded its regional reach, making it a strong player in the market.
Report Attribute |
Details |
Market size value in 2020 |
USD 522.3 million |
Revenue forecast in 2026 |
USD 706.3 million |
Growth Rate |
CAGR of 5.5% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2015 – 2017 |
Forecast period |
2019 – 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type |
Country scope |
U.S. |
Key companies profiled |
Medtronic plc; AngioDynamics, Inc.; Syneron Medical Ltd.; Lumenis Ltd.; Biolitec AG; Eufoton srl; Energist Group; Quanta Systems S.p.A.; Teleflex, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
革命制度党cing and purchase options |
Avail customized purchase options to meet your exact research needs.Explore purchase options |
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the U.S. varicose vein treatment devices market report based on type:
Type Outlook (Revenue, USD Million, 2015 - 2026)
Endovenous Ablation
Laser Ablation
Radiofrequency Ablation
Sclerotherapy
Surgical Ligation & Stripping
b.如果美国静脉曲张治疗设备市场ze was estimated at USD 491.7 million in 2019 and is expected to reach USD 522.3 million in 2020.
b.The U.S. varicose vein treatment devices market is expected to grow at a compound annual growth rate of 5.5% from 2019 to 2026 to reach USD 706.3 million by 2026.
b.Sclerotherapy dominated the type segment of the U.S. varicose vein treatment devices market in 2019. This is attributable to the easier accessibility, efficiency to treat varicose veins, and favorable reimbursement scenario.
b.Some key players operating in the U.S. varicose vein treatment devices market are Medtronic plc; AngioDynamics, Inc.; Syneron Medical Ltd.; Lumenis Ltd.; Biolitec AG; Eufoton srl; Energist Group; Quanta Systems S.p.A.; and Teleflex, Inc.
b.Key factors that are driving the market growth include the growth in investments by the manufacturers to introduce innovative products and an increase in the prevalence of varicose veins coupled with the growing geriatric population.
"The quality of research they have done for us has been excellent."